Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Excelsior Medical Co's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 71.32.
Excelsior Medical Co's Days Inventory for the
three
months ended in Mar. 2026 was 69.31.
Excelsior Medical Co's Days Payable for the
three
months ended in Mar. 2026 was 55.8.
Therefore, Excelsior Medical Co's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 84.83.
Excelsior Medical Co (TPE:4104) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Excelsior Medical Co Cash Conversion Cycle Related Terms
Excelsior Medical Co Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Excelsior Medical Co's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4104 vs MCK, COR, CAH: Cash Conversion Cycle Comparison
For the Medical Distribution subindustry, Excelsior Medical Co's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Excelsior Medical Co Cash Conversion Cycle vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Excelsior Medical Co's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Excelsior Medical Co's Cash Conversion Cycle falls into.
Excelsior Medical Co Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Excelsior Medical Co's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Excelsior Medical Co (TPE:4104) has a Cash Conversion Cycle of 84.83 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Excelsior Medical Co and its competitors.
Is Excelsior Medical Co's Cash Conversion Cycle too high?
Excelsior Medical Co's current Cash Conversion Cycle is 84.83. The Medical Distribution industry median Cash Conversion Cycle is 50.89. Excelsior Medical Co's value of 84.83 is 66.7% above this industry median. Overall, Excelsior Medical Co has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Excelsior Medical Co's Cash Conversion Cycle compare to MCK and COR?
Excelsior Medical Co's Cash Conversion Cycle of 84.83 can be compared against companies in the Medical Distribution industry. The industry median Cash Conversion Cycle is 50.89. Excelsior Medical Co's value of 84.83 is 66.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Distribution company?
The median Cash Conversion Cycle among Medical Distribution companies is 50.89, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Excelsior Medical Co's current Cash Conversion Cycle of 84.83 is 66.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Excelsior Medical Co and its competitors. For the Medical Distribution industry, the median Cash Conversion Cycle is 50.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Excelsior Medical Co's current Cash Conversion Cycle is 84.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Excelsior Medical Co stock overvalued right now?
Based on GuruFocus' analysis, Excelsior Medical Co (TPE:4104) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.68, compared to a current price of NT$70.00 — trading 20.2% below its estimated fair value. The current Cash Conversion Cycle is 84.83 and 66.7% above the Medical Distribution industry median of 50.89. Excelsior Medical Co's overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Excelsior Medical Co (TPE:4104), the current Cash Conversion Cycle is 84.83 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Excelsior Medical Co (TPE:4104) Overvalued in 2026?
Based on GuruFocus' analysis, Excelsior Medical Co stock appears to be undervalued.
The current stock price of NT$70.00 is trading 20.2% below its estimated GF Value™ of NT$87.68.
GuruFocus considers Excelsior Medical Co to be Modestly Undervalued.
Key valuation signals for TPE:4104:
Cash Conversion Cycle: 84.83
GF Value™: NT$87.68 vs. price of NT$70.00 (20.2% below fair value)
Industry Position: 66.7% above the Medical Distribution median
No single metric tells the full story. See the TPE:4104 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Excelsior Medical Co Ltd is engaged in the sale of medical supplies and medicines, home medical devices, and medical equipment with brand names of local and foreign manufacturers. Its product offerings include Fasflo hollow fiber dialyzer, Renabio sodium chloride injection, acid concentrates, Sunder blood purification tubing set, JMS blood bags, etc. The Group's reportable segments include Excelsior, Dynamic, Arich, and Others. Maximum revenue is generated from the Excelsior segment. Geographically, it derives key revenue from Taiwan and also has a presence in Hong Kong, China, the Philippines, Malaysia, and Indonesia.
87GF Score
Get the complete analysis for TPE:4104
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4104 has been successfully added to your 
